This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Current Oncology Reports Open Access 13 January 2021
-
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Leukemia Open Access 16 January 2019
-
Precision therapy for acute myeloid leukemia
Journal of Hematology & Oncology Open Access 05 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184–198.
Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 1856–1862.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.
Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2011; 117: 2145–2155.
Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28: 4339–4345.
Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993.
Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294–3301.
Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104: 4202–4209.
Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012; 119: 5133–5143.
Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31: 3110–3118.
Rollig C, Müller-Tidow C, Hüttmann A, Kunzmann V, Baldus CD, Brandts CH et al. Sorafenib versus placebo in addition to standard therapy in adult patients ≤60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled soraml trial. Blood 2012; 120, Abstract 144.
Acknowledgements
This study was supported in part by the National Institutes of Health through the University of Texas MD Anderson Cancer Center Support Grant CA016672 and by an educational grant from Onyx/Bayer Pharmaceuticals.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
FR has received research funding from Bayer and Onyx Pharmaceuticals and has been a member of advisory boards with Bayer and Onyx Pharmaceuticals. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ravandi, F., Arana Yi, C., Cortes, J. et al. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28, 1543–1545 (2014). https://doi.org/10.1038/leu.2014.54
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.54
This article is cited by
-
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Current Oncology Reports (2021)
-
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Leukemia (2020)
-
Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia
Current Treatment Options in Oncology (2020)
-
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Leukemia (2019)
-
Precision therapy for acute myeloid leukemia
Journal of Hematology & Oncology (2018)